VERITAS Vision System Is Introduced by Johnson & Johnson

Johnson & Johnson Vision,* a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, today announced the global availability of the VERITAS Vision System, a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety, surgeon efficiency and comfort.

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting.

Approximately 50% of people over the age of 75 have cataracts1 and cataract surgery is one of the most common outpatient procedures performed today with a success rate of approximately 98%.2 Phacoemulsification is the most common cataract surgery technique3 and allows surgeons to effectively emulsify and efficiently remove the eye’s internal lens when it has become cloudy from cataracts. It is a delicate procedure that requires significant effort and control, which can be taxing on the surgeon. Equipment that surgeons can rely on through surgery is critical to optimizing the circumstances for surgical success.

“In my experience, the advancements in fluidics management and usability of the VERITAS Vision System have made a marked improvement in safety and stability of the phaco procedure,” said Jason Jones, M.D.§, Jones Eye Clinic, Sioux City, Iowa. “I’ve found I can glide through any lens density with less surge, and the level of chamber stability I’ve experienced with VERITAS gives me more confidence to take advantage of Venturi mode, the more powerful phaco setting.”

“Surgeon-centered equipment design is vital for an exacting and taxing procedure like phacoemulsification,” said Dr. Marco Tavolato, Head of Eye Centre, Chioggia Hospital, Italy.** “The advancements Johnson & Johnson Vision has made in phaco technology reinforce that the company is listening and tailoring innovations to surgeons’ needs. From safety features like Hybrid Fluidics Technology, to the nuances of a more ergonomic design for comfort and control, these advancements have made a measurable difference in my surgical day, and ease even the most challenging phaco cases.”

The VERITAS Vision System features several innovations to provide a better surgical experience, including:

  • Less surge, more stability
    • Hybrid Fluidics Technology minimizes post-occlusion surge to protect intraocular structures and provide exceptional chamber stability.††,‡‡
    • Intelligent Occlusion Sensing Technologies automatically respond to occlusions to preserve a calm, stable chamber even in dense cataract cases.§§
  • Exceptional phacoemulsification efficiency
    • Built using the company’s leading WHITESTAR technology combined with elliptical tip movement for ultra-smooth cutting, even in dense or advanced cataracts, providing an efficient lens extraction that uses less energy.***
    • Dual Pump System allows access to both Peristaltic and Venturi pumps with on-demand transition between the two at every step, allowing surgeons to adapt to clinical needs.‡‡
  • Surgeon-centered ergonomics for maneuverability and comfort
    • Between 52-80% of ophthalmologists report back and neck pain because of their work4 and 43% take breaks during surgery due to pain.5
    • An ergonomically designed foot pedal provides total control and a more comfortable experience.†††

“On top of providing a safe and stable procedure for cataract patients, we wanted to also offer a more efficient and comfortable phacoemulsification experience for surgeons, especially knowing most will perform multiple cataract surgeries every day,” said Warren Foust, Worldwide President, Surgical at Johnson & Johnson Vision.‡‡‡ “Our VERITAS Vision System delivers high-performing, reliable tools for a smooth, effective cataract surgery for patients while also prioritizing surgeon well-being.”

The VERITAS Vision System is the latest addition to the company’s full suite of industry leading products for the treatment of cataracts. The global launch comes as the Johnson & Johnson Vision celebrates two 20-year anniversaries: WHITESTAR micropulse technology, a major advancement in phacoemulsification efficiency10, the TECNIS Family of IOLs, which established the company’s legacy of innovation in cataract treatment.

The VERITAS Vision System is now available for ophthalmologists across the United States, Europe and select markets in the Asia Pacific region to use in their treatment of cataracts and will be available later this year in Chile and Brazil.


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy